The impact of depot gnrh agonist on amh levels in healthy reproductive-aged women

Journal of Clinical Endocrinology and Metabolism

Volumn 98, Issue 12, 2013, Pages

  Su, H Irene ^a   Maas, Kevin ^a   Sluss, Patrick M ^b   Chang, R Jeffrey ^a   Hall, Janet E ^b   Joffe, Hadine ^b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; FOLLITROPIN; LEUPRORELIN; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; PROGESTERONE;

ADULT; ARTICLE; COMPARATIVE STUDY; DOWN REGULATION; DRUG EFFECT; EARLY FOLLICULAR PHASE; ESTRADIOL BLOOD LEVEL; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; HUMAN EXPERIMENT; LUTEINIZING HORMONE BLOOD LEVEL; MENSTRUAL CYCLE; MIDDLE AGED; MIDLUTEAL PHASE; NORMAL HUMAN; OUTCOME ASSESSMENT; OVARIAN RESERVE; PREMENOPAUSE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; TIME SERIES ANALYSIS; TREATMENT DURATION; YOUNG ADULT;

ADOLESCENT; ADULT; ANTI-MULLERIAN HORMONE; BIOLOGICAL MARKERS; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; FEMALE; FERTILITY AGENTS, FEMALE; FERTILITY PRESERVATION; GONADOTROPIN-RELEASING HORMONE; GRANULOSA CELLS; HUMANS; LEUPROLIDE; MENSTRUAL CYCLE; MIDDLE AGED; OVARY; YOUNG ADULT;

EID: 84889839245     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2410     Document Type: Article

References (21)

1. Weenen C, Laven JS, Von Bergh AR, et al. Anti-müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10: 77-83
2. van Rooij IA, Broekmans FJ, te Velde ER, et al. Serum anti-müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065-3071
3. Freeman EW, Sammel MD, Lin H, Gracia CR. Anti-mullerian hormone as a predictor of time to menopause in late reproductive age women. J Clin Endocrinol Metab. 2012;97:1673-1680
4. Steiner AZ, Herring AH, Kesner JS, et al. Antimüllerian hormone as a predictor of natural fecundability in women aged 30-42 years. Obstet Gynecol. 2011;117:798-804
5. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24:2917-2931
6. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER, Broekmans FJ. Anti-müllerian hormone levels in the spontaneous menstrual cycle do not show substantial fluctuation. J Clin Endocrinol Metab. 2006;91:4057-4063
7. Steiner AZ, Stanczyk FZ, Patel S, Edelman A. Antimullerian hormone and obesity: insights in oral contraceptive users. Contraception. 2010;81:245-248
8. Streuli I, Fraisse T, Pillet C, Ibecheole V, Bischof P, de Ziegler D. Serum antimüllerian hormone levels remain stable throughout the menstrual cycle and after oral or vaginal administration of synthetic sex steroids. Fertil Steril. 2008;90:395-400
9. Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropinreleasing hormone analogue triptorelin on the occurrence of chemotherapy- induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306:269-276
10. Peng C, Fan NC, Ligier M, Väänänen J, Leung PC. Expression and regulation of gonadotropin-releasing hormone (GnRH) and GnRH receptor messenger ribonucleic acids in human granulosa-luteal cells. Endocrinology. 1994;135:1740-1746
11. Joffe H, White DP, Crawford SL, et al. Adverse effects of induced hot flashes on objectively recorded and subjectively reported sleep: results of a gonadotropin-releasing hormone agonist experimental protocol. Menopause. 2013;20:905-914
12. Joffe H, Crawford S, Economou N, et al. A gonadotropin-releasing hormone agonist model demonstrates that nocturnal hot flashes interrupt objective sleep. Sleep. 2013;36(12)
13. Rosenfield RL, Wroblewski K, Padmanabhan V, Littlejohn E, Mortensen M, Ehrmann DA. Antimüllerian hormone levels are independently related to ovarian hyperandrogenism and polycystic ovaries. Fertil Steril. 2012;98:242-249
14. Nelson RE, Grebe SK, OKane DJ, Singh RJ. Liquid chromatography- tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma. Clin Chem. 2004; 50:373-384
15. Jayaprakasan K, Campbell BK, Hopkisson JF, Clewes JS, Johnson IR, Raine-Fenning NJ. Effect of pituitary desensitization on the early growing follicular cohort estimated using anti-Mullerian hormone. Hum Reprod. 2008;23:2577-2583
16. van Disseldorp J, Lambalk CB, Kwee J, et al. Comparison of interand intra-cycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod. 2010;25:221-227
17. Anderson RA, Themmen AP, Al-Qahtani A, Groome NP, Cameron DA. The effects of chemotherapy and long-term gonadotrophin suppression on the ovarian reserve in premenopausal women with breast cancer. Hum Reprod. 2006;21:2583-2592
18. Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy Ch, Englert Y. Stable serum levels of anti-Müllerian hormone during the menstrual cycle: a prospective study in normo-ovulatory women. Hum Reprod. 2007;22:1837-1840
19. Mörse H, Elfving M, Lindgren A, Wölner-Hanssen P, Andersen CY, Øra I. Acute onset of ovarian dysfunction in young females after start of cancer treatment. Pediatr Blood Cancer. 2013;60: 676- 681
20. Fanchin R, Schonäuer LM, Righini C, Frydman N, Frydman R, Taieb J. Serum anti-Müllerian hormone dynamics during controlled ovarian hyperstimulation. Hum Reprod. 2003;18:328-332
21. Young J, Rey R, Couzinet B, Chanson P, Josso N, Schaison G. Antimüllerian hormone in patients with hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 1999;84:2696-2699